We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Vaxcyte Inc
2 own
2 watching
Current Price
$51.25
$-0.64
(-1.23%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
4,132.84M
52-Week High
54.8382
52-Week Low
17.44
Average Volume
0.46M
Dividend Yield
--
P/E Ratio
--
Market Capitalization4,132.84M52-Week High54.838252-Week Low17.44Average Volume0.46MDividend Yield--P/E Ratio--What does the Vaxcyte Inc do?
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Read More
How much money does Vaxcyte Inc make?
News & Events about Vaxcyte Inc.
Globe Newswire
1month ago
SAN CARLOS, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of ...
PR Newswire
1month ago
Thinking about buying stock in CNS Pharmaceuticals, Revelation Biosciences, Oblong, Vaxcyte, or Peabody Energy? Thinking about buying stock in CNS Pharmaceuticals, Revelation Biosciences, Oblong, Vaxcyte, or Peabody Energy? PR Newswire NEW YORK, April 17, 2023 NEW YORK, April 17, 2023 /PRNewswire...
Ticker Report
3 months ago
Vaxcyte (NASDAQ:PCVX Get Rating) had its price objective reduced by Guggenheim from $66.00 to $65.00 in a report released on Tuesday , Benzinga reports. They currently have a buy rating on the stock. PCVX has been the topic of several other research reports. SVB Leerink reiterated an ...
Ticker Report
3 months ago
Vaxcyte (NASDAQ:PCVX Get Rating) had its price target decreased by Guggenheim from $66.00 to $65.00 in a report published on Tuesday, Benzinga reports. Guggenheim currently has a buy rating on the stock. Several other brokerages have also commented on PCVX. BTIG Research started coverage on ...
Globe Newswire
3 months ago
-- Infant Phase 2 Study Initiation Expected in the Second Quarter of 2023, with Initial Topline Safety, Tolerability and Immunogenicity Data by 2025 -- -- Based on Positive Topline VAX-24 Phase 1/2 Proof-of-Concept Study Results in Adults, FDA Supported Initiation of Pediatric Program in Infants -- ...
Frequently Asked Questions
Frequently Asked Questions
What is Vaxcyte Inc share price today?
Can Indians buy Vaxcyte Inc shares?
How can I buy Vaxcyte Inc shares from India?
Can Fractional shares of Vaxcyte Inc be purchased?
What are the documents required to start investing in Vaxcyte Inc stocks?
What is today’s traded volume of Vaxcyte Inc?
What is today’s market capitalisation of Vaxcyte Inc?
What is the 52-Week High and Low Range of Vaxcyte Inc?
What percentage is Vaxcyte Inc down from its 52-Week High?
What percentage is Vaxcyte Inc up from its 52-Week Low?
Current Price
$51.25
$-0.64
(-1.23%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.